Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cancer cell antioxidant systems refer to the network of molecules and enzymes that cancer cells use to maintain redox homeostasis by neutralizing reactive oxygen species (ROS). These systems are often upregulated in cancer, enabling tumor cells to survive high oxidative stress, resist apoptosis, and develop resistance to therapies. This adaptive response is known as "redox reprogramming," where both ROS and antioxidants are maintained at elevated levels. Key components include enzymatic antioxidants like superoxide dismutases (SODs), catalase (CAT), glutathione peroxidases (GPXs), peroxiredoxins (PRDXs), and the thioredoxin system. Non-enzymatic antioxidants include glutathione (GSH), vitamins C/E, melatonin, and ubiquinone. The Nrf2/KEAP1 signaling axis is a major regulatory pathway. Targeting these systems can sensitize tumors to therapy.
Inhibition of antioxidant enzymes or pathways to induce ROS accumulation and cell death. Modulation of Nrf2 signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer Cell Antioxidant Systems.